These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21328541)

  • 1. Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis.
    Festjens N; Bogaert P; Batni A; Houthuys E; Plets E; Vanderschaeghe D; Laukens B; Asselbergh B; Parthoens E; De Rycke R; Willart MA; Jacques P; Elewaut D; Brouckaert P; Lambrecht BN; Huygen K; Callewaert N
    EMBO Mol Med; 2011 Apr; 3(4):222-34. PubMed ID: 21328541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SapM mutation to improve the BCG vaccine: Genomic, transcriptomic and preclinical safety characterization.
    Festjens N; Vandewalle K; Houthuys E; Plets E; Vanderschaeghe D; Borgers K; Van Hecke A; Tiels P; Callewaert N
    Vaccine; 2019 Jun; 37(27):3539-3551. PubMed ID: 31122861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
    Gengenbacher M; Nieuwenhuizen N; Vogelzang A; Liu H; Kaiser P; Schuerer S; Lazar D; Wagner I; Mollenkopf HJ; Kaufmann SH
    mBio; 2016 May; 7(3):. PubMed ID: 27222470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of anti-mycobacterial efficacy in mice over time following vaccination with Mycobacterium bovis bacillus Calmette-Guérin.
    Ozeki Y; Hirayama Y; Takii T; Yamamoto S; Kobayashi K; Matsumoto S
    Vaccine; 2011 Sep; 29(40):6881-7. PubMed ID: 21803102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo persistence and protective efficacy of the bacille Calmette Guerin vaccine overexpressing the HspX latency antigen.
    Spratt JM; Britton WJ; Triccas JA
    Bioeng Bugs; 2010; 1(1):61-5. PubMed ID: 21327127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
    Majlessi L; Brodin P; Brosch R; Rojas MJ; Khun H; Huerre M; Cole ST; Leclerc C
    J Immunol; 2005 Mar; 174(6):3570-9. PubMed ID: 15749894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination.
    Flaherty DK; Vesosky B; Beamer GL; Stromberg P; Turner J
    J Leukoc Biol; 2006 Dec; 80(6):1262-71. PubMed ID: 16968819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated induction of mycobacterial antigen-specific CD8+ T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guérin.
    Begum D; Umemura M; Yahagi A; Okamoto Y; Hamada S; Oshiro K; Matsuzaki G
    Immunology; 2009 Dec; 128(4):556-63. PubMed ID: 19930045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice.
    Aldwell FE; Tucker IG; de Lisle GW; Buddle BM
    Infect Immun; 2003 Jan; 71(1):101-8. PubMed ID: 12496154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guérin ΔureC::hly Δpdx1 in mice.
    Gengenbacher M; Vogelzang A; Schuerer S; Lazar D; Kaiser P; Kaufmann SH
    mBio; 2014 Jun; 5(3):e01262-14. PubMed ID: 24895310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
    Valencia-Hernandez AM; Zhao G; Miranda-Hernandez S; Segura-Cerda CA; Pedroza-Roldan C; Seifert J; Aceves-Sanchez MJ; Burciaga-Flores M; Gutierrez-Ortega A; Del Pozo-Ramos L; Flores-Valdez MA; Kupz A
    Vaccine; 2024 Oct; 42(24):126291. PubMed ID: 39241355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model.
    Hedhli D; Denis O; Barkan D; Daffé M; Glickman MS; Huygen K
    PLoS One; 2013; 8(10):e76442. PubMed ID: 24146869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
    PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
    Brandt L; Skeiky YA; Alderson MR; Lobet Y; Dalemans W; Turner OC; Basaraba RJ; Izzo AA; Lasco TM; Chapman PL; Reed SG; Orme IM
    Infect Immun; 2004 Nov; 72(11):6622-32. PubMed ID: 15501795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.
    Castillo-Rodal AI; Castañón-Arreola M; Hernández-Pando R; Calva JJ; Sada-Díaz E; López-Vidal Y
    Infect Immun; 2006 Mar; 74(3):1718-24. PubMed ID: 16495544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.